Novavax (NASDAQ: NVAX) announced the initiation of a Phase 3 clinical trial, known as Resolve, of its respiratory syncytial virus ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Novavax Reports Third Quarter 2015 Financial ResultsNovember 9, 2015 6:55 AM Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older AdultsNovember 9, 2015 6:50 AM